|
IL160307A0
(en)
|
2001-08-31 |
2004-07-25 |
Univ Rockefeller |
Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
|
|
JP2005508978A
(ja)
*
|
2001-11-02 |
2005-04-07 |
ファイザー・プロダクツ・インク |
Ｐｄｅ９阻害薬によるインスリン抵抗性症候群及び２型糖尿病の治療
|
|
US20030195205A1
(en)
*
|
2001-11-02 |
2003-10-16 |
Pfizer Inc. |
PDE9 inhibitors for treating cardiovascular disorders
|
|
CA2468156A1
(en)
|
2001-12-06 |
2003-06-19 |
Merck & Co., Inc. |
Azolopyrimidinone compounds and their use
|
|
ES2280596T3
(es)
*
|
2001-12-29 |
2007-09-16 |
Novo Nordisk A/S |
Uso combinado de un compuesto de glp-1 y un inhibidor de una aldosa reductasa.
|
|
IS1935B
(is)
*
|
2002-03-19 |
2004-06-16 |
Actavis Group Hf. |
Fósínópríl lyfjasamsetning
|
|
ATE478872T1
(de)
*
|
2002-03-28 |
2010-09-15 |
Ustav Ex Botan Av Cr V V I I O |
Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
|
|
DE10238724A1
(de)
*
|
2002-08-23 |
2004-03-04 |
Bayer Ag |
Alkyl-substituierte Pyrazolpyrimidine
|
|
DE10238723A1
(de)
*
|
2002-08-23 |
2004-03-11 |
Bayer Ag |
Phenyl-substituierte Pyrazolyprimidine
|
|
DE10238722A1
(de)
|
2002-08-23 |
2004-03-11 |
Bayer Ag |
Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
|
|
US20040220186A1
(en)
*
|
2003-04-30 |
2004-11-04 |
Pfizer Inc. |
PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
|
|
DE10320785A1
(de)
*
|
2003-05-09 |
2004-11-25 |
Bayer Healthcare Ag |
6-Arylmethyl-substituierte Pyrazolopyrimidine
|
|
DE102004004142A1
(de)
*
|
2003-05-09 |
2004-11-25 |
Bayer Healthcare Ag |
6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine
|
|
US8044060B2
(en)
|
2003-05-09 |
2011-10-25 |
Boehringer Ingelheim International Gmbh |
6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
|
|
WO2004099211A1
(de)
*
|
2003-05-09 |
2004-11-18 |
Bayer Healthcare Ag |
6-cyclylmethyl- und 6-alkylmethyl-substituierte pyrazolopyrimidine
|
|
WO2005041972A1
(en)
*
|
2003-10-31 |
2005-05-12 |
Pfizer Products Inc. |
Phosphodiesterase 9 inhibition as treatment for obesity-related conditions
|
|
EP1734963A4
(en)
|
2004-04-02 |
2008-06-18 |
Merck & Co Inc |
METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
|
|
WO2005105780A2
(en)
*
|
2004-04-28 |
2005-11-10 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of rock and other protein kinases
|
|
AU2005245240B2
(en)
*
|
2004-05-20 |
2010-04-29 |
Scimar Ltd. |
Use of drug combinations for treating insulin resistance
|
|
CA2612176C
(en)
|
2005-06-14 |
2015-02-17 |
Aska Pharmaceutical Co., Ltd. |
Dihydrothieno[2,3-d]pyramidine-6-carboxylic acid derivatives as pde9 inhibitors
|
|
US20080194592A1
(en)
*
|
2005-08-23 |
2008-08-14 |
Intra-Cellular Therapies, Inc. |
Organic Compounds
|
|
AU2007282678B2
(en)
*
|
2006-08-08 |
2012-09-27 |
Aska Pharmaceutical Co., Ltd. |
Quinazoline derivative
|
|
WO2008028914A1
(en)
|
2006-09-07 |
2008-03-13 |
Nycomed Gmbh |
Combination treatment for diabetes mellitus
|
|
AU2007299920A1
(en)
*
|
2006-09-19 |
2008-03-27 |
Braincells, Inc. |
PPAR Mediated Modulation of Neurogenesis
|
|
US8299080B2
(en)
|
2006-12-13 |
2012-10-30 |
Aska Pharmaceutical Co., Ltd. |
Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor
|
|
WO2008072778A1
(ja)
|
2006-12-13 |
2008-06-19 |
Aska Pharmaceutical Co., Ltd. |
尿路系疾患の処置剤
|
|
ITMI20070140A1
(it)
*
|
2007-01-30 |
2008-07-31 |
Campagnolo Srl |
Dispositivo di interazione uomo-bicicletta
|
|
US20100144864A1
(en)
*
|
2007-04-05 |
2010-06-10 |
Ironwood Pharmaceuticals, Inc. |
Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
|
|
RS52166B
(sr)
*
|
2007-05-11 |
2012-08-31 |
Pfizer Inc. |
Amino-heterociklična jedinjenja
|
|
KR101560844B1
(ko)
|
2007-06-04 |
2015-10-15 |
벤-구리온 유니버시티 오브 더 네게브 리서치 앤드 디벨럽먼트 어쏘러티 |
트라이-아릴계 화합물 및 이를 포함하는 조성물
|
|
JP5498392B2
(ja)
*
|
2007-11-30 |
2014-05-21 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
１，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
|
|
CN101998957B
(zh)
|
2008-02-29 |
2013-06-05 |
康塞特医药品有限公司 |
取代的黄嘌呤衍生物
|
|
UA105362C2
(en)
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
|
KR20110063447A
(ko)
|
2008-09-08 |
2011-06-10 |
베링거 인겔하임 인터내셔날 게엠베하 |
피라졸로피리미딘 및 ｃｎｓ 장애의 치료를 위한 이들의 용도
|
|
EP2348857B1
(en)
|
2008-10-22 |
2016-02-24 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
US8329914B2
(en)
|
2008-10-31 |
2012-12-11 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
|
TWI404721B
(zh)
|
2009-01-26 |
2013-08-11 |
Pfizer |
胺基－雜環化合物
|
|
US20110053961A1
(en)
|
2009-02-27 |
2011-03-03 |
Concert Pharmaceuticals, Inc. |
Substituted xanthine derivatives
|
|
PT2414363E
(pt)
|
2009-03-31 |
2014-02-26 |
Boehringer Ingelheim Int |
Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a
|
|
JP6166534B2
(ja)
|
2009-08-05 |
2017-07-19 |
イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． |
新規調節タンパク質および阻害剤
|
|
AR078793A1
(es)
|
2009-10-27 |
2011-12-07 |
Orion Corp |
Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
|
|
JP2013520502A
(ja)
|
2010-02-25 |
2013-06-06 |
メルク・シャープ・エンド・ドーム・コーポレイション |
有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
|
|
EP2603511B1
(en)
|
2010-08-12 |
2017-03-15 |
Boehringer Ingelheim International GmbH |
6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
|
|
RS54834B1
(sr)
|
2010-09-07 |
2016-10-31 |
Astellas Pharma Inc |
Jedinjenja pirazolokvinolina
|
|
EP2619208B1
(en)
|
2010-09-20 |
2016-11-09 |
Ironwood Pharmaceuticals, Inc. |
Imidazotriazinone compounds
|
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
|
SG192941A1
(en)
|
2011-02-25 |
2013-09-30 |
Merck Sharp & Dohme |
Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
|
|
WO2013013052A1
(en)
|
2011-07-19 |
2013-01-24 |
Concert Pharmaceuticals, Inc. |
Substituted xanthine derivatives
|
|
BR112015007731B1
(pt)
|
2011-10-10 |
2022-05-31 |
H. Lundbeck A/S |
Composto, composição farmacêutica que o compreende e uso do mesmo
|
|
BR112014018199A8
(pt)
|
2012-01-26 |
2021-03-02 |
H Lundbeck As |
inibidores da pde9 com cadeia principal imidazo triazinona, composição farmacêutica que os compreende, uso dos referidos inibidores e processo para sua preparação
|
|
HK1206726A1
(en)
|
2012-03-19 |
2016-01-15 |
Ironwood Pharmaceuticals, Inc. |
Imidazotriazinone compounds
|
|
US20130315891A1
(en)
|
2012-05-25 |
2013-11-28 |
Matthew Charles |
Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
|
|
US20130323222A1
(en)
|
2012-06-04 |
2013-12-05 |
Matthew Charles |
Human tissue kallikrein 1 glycosylation isoforms
|
|
RU2015106909A
(ru)
|
2012-08-02 |
2016-09-27 |
Мерк Шарп И Доум Корп. |
Антидиабетические трициклические соединения
|
|
WO2014024125A1
(en)
|
2012-08-08 |
2014-02-13 |
Celon Pharma S.A. |
Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors
|
|
CN102786525B
(zh)
|
2012-08-08 |
2014-12-17 |
中山大学 |
N-取代吡唑并[3,4-d]嘧啶酮类化合物、其制备方法及其应用
|
|
KR20150118158A
(ko)
|
2013-02-22 |
2015-10-21 |
머크 샤프 앤드 돔 코포레이션 |
항당뇨병 비시클릭 화합물
|
|
WO2014139388A1
(en)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
JP2015067538A
(ja)
*
|
2013-09-26 |
2015-04-13 |
株式会社アイエイアイ |
血糖値降下剤
|
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
MX2016005995A
(es)
|
2013-11-05 |
2016-08-17 |
Ben-Gurion Univ Of The Negev Res And Dev Authority |
Compuestos para el tratamiento de diabetes y complicaciones de la enfermedad derivadas de la misma.
|
|
CA2981791A1
(en)
|
2014-04-18 |
2015-10-22 |
Concert Pharmaceuticals, Inc. |
Methods of treating hyperglycemia
|
|
PT3865484T
(pt)
|
2015-07-07 |
2024-01-30 |
H Lundbeck As |
Inibidor da pde9 com esqueleto de imidazo pirazinona para tratamento de doenças periféricas
|
|
US20180072741A1
(en)
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyrimidine compounds and uses thereof
|
|
WO2018049214A1
(en)
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
|
|
CN115819417A
(zh)
|
2016-09-09 |
2023-03-21 |
因赛特公司 |
作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途
|
|
US11072602B2
(en)
|
2016-12-06 |
2021-07-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
|
EP3558298B1
(en)
|
2016-12-20 |
2026-03-11 |
Merck Sharp & Dohme LLC |
Antidiabetic spirochroman compounds
|
|
WO2018152220A1
(en)
|
2017-02-15 |
2018-08-23 |
Incyte Corporation |
Pyrazolopyridine compounds and uses thereof
|
|
AU2018230478B2
(en)
|
2017-03-09 |
2025-01-23 |
Diamedica Inc. |
Dosage forms of tissue kallikrein 1
|
|
CN115746003B
(zh)
*
|
2017-05-26 |
2024-08-09 |
卡都瑞恩医药公司 |
制备和使用pde9抑制剂的方法
|
|
AU2018281131B2
(en)
|
2017-06-08 |
2022-01-20 |
Merck Sharp & Dohme Corp. |
Pyrazolopyrimidine PDE9 inhibitors
|
|
US10722495B2
(en)
|
2017-09-08 |
2020-07-28 |
Incyte Corporation |
Cyanoindazole compounds and uses thereof
|
|
US10752635B2
(en)
|
2018-02-20 |
2020-08-25 |
Incyte Corporation |
Indazole compounds and uses thereof
|
|
EP3755703B1
(en)
|
2018-02-20 |
2022-05-04 |
Incyte Corporation |
N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer
|
|
US10745388B2
(en)
|
2018-02-20 |
2020-08-18 |
Incyte Corporation |
Indazole compounds and uses thereof
|
|
US11299473B2
(en)
|
2018-04-13 |
2022-04-12 |
Incyte Corporation |
Benzimidazole and indole compounds and uses thereof
|
|
CA3100988A1
(en)
|
2018-05-25 |
2019-11-28 |
Imara Inc. |
Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one
|
|
US10899755B2
(en)
|
2018-08-08 |
2021-01-26 |
Incyte Corporation |
Benzothiazole compounds and uses thereof
|
|
CA3110680A1
(en)
|
2018-08-31 |
2020-03-05 |
Imara Inc. |
Pde9 inhibitors for treating sickle cell disease
|
|
WO2020068729A1
(en)
|
2018-09-25 |
2020-04-02 |
Incyte Corporation |
Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators
|
|
BR112022002059A2
(pt)
|
2019-08-06 |
2022-06-07 |
Incyte Corp |
Formas sólidas de um inibidor de hpk1
|
|
US20240025904A1
(en)
*
|
2020-10-27 |
2024-01-25 |
Cardurion Pharmaceuticals, Inc. |
Pde9 inhibitors for treating cardiac failure
|